Whitney & Co’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Whitney & Co’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-60	Closed	–	–	503
2018 Q3	$0	Hold	60	–	–	﹤0.01%	558
2018 Q2	$0	Buy	+60	New	+$408	﹤0.01%	344

Other funds holding SRNE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Whitney & Co's SRNE Position: Q4 2018 in Review

Whitney & Co sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2018, closing a stake of 60 shares.

Whitney & Co first reported a position in SRNE in Q2 2018 and held it in 2 quarters. The position peaked at $0 in Q3 2018. 78 funds tracked by Wall St. Rank hold SRNE as of Q4 2018.

Whitney & Co reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
Whitney & Co sold 60 Sorrento Therapeutics, Inc. shares in Q4 2018.
Whitney & Co first reported a position in Sorrento Therapeutics, Inc. in Q2 2018 and held it in 2 quarters.
Whitney & Co's Sorrento Therapeutics, Inc. position peaked at $0 in Q3 2018.
78 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2018.

Based on Whitney & Co's 13F filing for Q4 2018, filed 7 Feb 2019.